(Q36266000)

13 August 2017

1 reference

title

Ranolazine: new approach for the treatment of stable angina pectoris (English)

1 reference

13 August 2017

1 reference

William C Stanley

1

1 reference

13 August 2017

publication date

1 September 2005

1 reference

Expert Review of Cardiovascular Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

3

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

821-829

1 reference

Current and future treatment strategies for refractory angina

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Ranolazine: a novel metabolic modulator for the treatment of angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Partial fatty acid oxidation inhibitors for stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.821

21 January 2018

Identifiers

DOI

10.1586/14779072.3.5.821

1 reference

13 August 2017

1 reference